Compare Stocks

The abrdn Bloomberg All Commodity Strategy K-1 Free ETF (BCI) is an exchange-traded fund that is based on the Bloomberg Commodity Total Return index. The fund seeks to outperform a broad-market commodity index through the active management of the fund`s collateral. The index includes 26 commodity futures with maturities of 1-3 months. BCI was launched on Mar 30, 2017 and is managed by Abrdn.

Eaton Vance Tax-Advantaged Global Dividend Income Fund is a closed ended equity mutual fund launched and managed by Eaton Vance Management. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating across diversified sectors. The fund primarily invests in dividend paying value stocks of companies. It employs fundamental analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the MSCI World Index. Eaton Vance Tax-Advantaged Global Dividend Income Fund was formed on November 14, 2003 and is domiciled in the United States.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.